News

Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose. The regulatory decision is

The facility will be constructed in the New Albany International Business Park. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and

The therapy is indicated to improve functional capacity and symptoms. The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the

Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to

The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science enterprises secure

Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia. The agreement grants Knight

The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan. The terms also include equity consideration and tiered royalties on

Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. This will provide an estimated 12% stake in the

The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that